Company Filing History:
Years Active: 2018
Title: Kwi Sung Park: Innovator in Vaccinia Virus Research
Introduction
Kwi Sung Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of virology, particularly in the development of vaccines. His work focuses on creating safer and more effective solutions for combating poxvirus infections.
Latest Patents
Kwi Sung Park holds a patent for the attenuated vaccinia virus KVAC103 strain. This strain was developed by subculturing a vaccinia virus strain 103 times in VERO cells. The KVAC103 strain exhibits significantly low toxicity and shows reduced skin lesions. Importantly, it effectively induces immune responses to poxvirus, making it a promising candidate for use as a poxvirus vaccine with fewer side effects.
Career Highlights
Kwi Sung Park is affiliated with the Korea Centers for Disease Control and Prevention. His role at this institution allows him to contribute to public health initiatives and advance research in infectious diseases. His innovative work has the potential to impact vaccine development significantly.
Collaborations
Some of his notable coworkers include Sang Gu Yeo and Ho Sun Son. Their collaborative efforts in research and development have furthered the understanding of poxvirus and vaccine efficacy.
Conclusion
Kwi Sung Park's contributions to vaccine research, particularly through his patent on the KVAC103 strain, highlight his commitment to improving public health. His work exemplifies the importance of innovation in the fight against infectious diseases.